AIM ImmunoTech (AIM) Capital Expenditures (2010 - 2021)
AIM ImmunoTech's (AIM) quarterly Capital Expenditures came in at $7000.0 in Q4 2021, down 22.22% YoY from $9000.0 in Q4 2020, and down 12.5% on a QoQ basis from $8000.0 in Q3 2021.
AIM ImmunoTech (AIM) Capital Expenditures (2010 - 2021) Analysis & Trends
AIM ImmunoTech (AIM) has 11 years of Capital Expenditures data on file, last reported at $7000.0 in Q4 2021.
- Quarterly Capital Expenditures fell 22.22% year-over-year to $7000.0 in Q4 2021, while the trailing twelve-month figure through Dec 2024 was $24000.0 (changed N/A YoY) and the FY2024 annual result came in at $18000.0, changed N/A from the prior year.
- Capital Expenditures fell to $7000.0 in Q4 2021, from $8000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $49000.0 in Q2 2019 to a low of $2000.0 in Q2 2020.
- A 5-year average of $10666.7 and a median of $7000.0 in 2020 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2020 — Capital Expenditures slumped 95.92% — and 2021, when it surged 100.0%.
- Tracing AIM's Capital Expenditures over 5 years: stood at $17000.0 in 2017, then sank by 82.35% to $3000.0 in 2018, then soared by 66.67% to $5000.0 in 2019, then soared by 80.0% to $9000.0 in 2020, then decreased by 22.22% to $7000.0 in 2021.
- The last three Capital Expenditures figures came in at $7000.0 (Q4 2021), $8000.0 (Q3 2021), and $9000.0 (Q4 2020), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 34.68 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.26 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 251.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -73.57 Mn |
| 10 | AIM ImmunoTech | 4.34 Mn | -5.62 Mn | 21,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 7,000.00 |
| Dec 31, 2021 | 7,000.00 |
| Sep 30, 2021 | 8,000.00 |
| Sep 30, 2021 | 8,000.00 |
| Dec 31, 2020 | 9,000.00 |
| Dec 31, 2020 | 9,000.00 |
| Sep 30, 2020 | 4,000.00 |
| Sep 30, 2020 | 4,000.00 |
| Jun 30, 2020 | 2,000.00 |
| Jun 30, 2020 | 2,000.00 |
| Mar 31, 2020 | 7,000.00 |
| Mar 31, 2020 | 7,000.00 |
| Sep 30, 2019 | 5,000.00 |
| Sep 30, 2019 | 5,000.00 |
| Jun 30, 2019 | 49,000.00 |
| Jun 30, 2019 | 49,000.00 |
| Mar 31, 2019 | 14,000.00 |
| Mar 31, 2019 | 14,000.00 |
| Dec 31, 2018 | 3,000.00 |
| Dec 31, 2018 | 3,000.00 |